Lipoprotein(a) Concentration and Achieving Target Values of Low-Density Lipoprotein Cholesterol Calculated by Different Equations
Open Access
Abstract
Background: Low-density lipoprotein cholesterol (LDL-C) is a major cardiovascular risk factor and an indicator of hypolipidemic therapy effectiveness. However, direct and calculated methods for determining “LDL-C” present the sum of the cholesterol in all apoB-containing lipoproteins, including lipoprotein(a) [Lp(a)]. There has been an ongoing debate about the correctness of LDL-C in patients with elevated Lp(a) concentrations up to now. The aim of this study was to evaluate the effect of Lp(a) concentration on the LDL-C calculated by different equations. Methods: The study included the results of fasting lipids and Lp(a) concentration of 566 measurements from 283 patients (before and after lipid-lowering therapy prescribing, after exclusion of 17 patients with incomplete data). LDL-C and LDL-C corrected for Lp(a)-cholesterol (LDL-Ccorr) were calculated by Friedewald, Martin–Hopkins, and Sampson equations. Results: We assessed 566 measurements of lipids and Lp(a). The number of values reclassified to a higher risk category was 10% and 13% with Martin–Hopkins and Sampson equations compared to the Friedewald formula. The percentage of Lp(a)-cholesterol (Lp(a)-C) in the LDL-C calculated by three formulas was up to 90% or more depending on the concentration of LDL-C and Lp(a). When stratified by clinically significant LDL-C thresholds, the proportion of values LDL-Ccorr reclassified to a lower risk category ranged from 30 to 59%. Conclusion: Comparison of LDL-C concentrations calculated by Friedewald, Martin–Hopkins, and Sampson equations showed high consistency in patients without elevated triglycerides. The LDLcorr is reasonable to use in patients with Lp(a) concentration ≥ 30 and ≥41 mg/dL when using the Martin–Hopkins and Sampson equations, respectively. These data may help clinicians interpret LDL-C goal attainment in patients with elevated Lp(a) and avoid misclassification driven by the Lp(a)-cholesterol component.Keywords
This publication has 29 references indexed in Scilit:
- The Brussels International Declaration on Lipoprotein(a) Testing and ManagementAtherosclerosis, 2025
- Impact of Lipoprotein(a) Level on Low-Density Lipoprotein Cholesterol– or Apolipoprotein B–Related Risk of Coronary Heart DiseaseJACC, 2024
- Quantification of LDL-Cholesterol Corrected for Molar Concentration of Lipoprotein(a)Cardiovascular Drugs and Therapy, 2022
- More accurate LDL-C calculation: Externally validated, guideline endorsedClinica Chimica Acta, 2020
- A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and/or HypertriglyceridemiaJAMA Cardiology, 2020
- Comparing a novel equation for calculating low-density lipoprotein cholesterol with the Friedewald equation: A VOYAGER analysisClinical Biochemistry, 2019
- Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative UltracentrifugationJAMA Cardiology, 2018
- Comparison of a Novel Method vs the Friedewald Equation for Estimating Low-Density Lipoprotein Cholesterol Levels From the Standard Lipid ProfileJAMA, 2013
- Lipoprotein(a)-cholesterol: A significant component of serum cholesterolClinica Chimica Acta, 2011
- Enzyme immunoassay of lipoprotein(a)Bulletin of Experimental Biology and Medicine, 1995